Dynavax Technologies Inc., of Berkeley, Calif., appointed Deborah Smeltzer vice president of operations and chief financial officer.
Ecopia BioSciences Inc., of Montreal, said Chris Farnet's chief scientific officer position has evolved to special scientific adviser to the president and CEO.
Endo Pharmaceuticals Inc., of Chadds Ford, Pa., appointed Mark Gossett senior vice president, commercial business, and John Buckingham senior vice president, alliance management.
Enzon Pharmaceuticals Inc., of Bridgewater, N.J., appointed Phillip Renfro to its board, and Craig Tooman executive vice president strategic planning and corporate communications.
Genentech Inc., of South San Francisco, appointed David Ebersman senior vice president, finance; Patrick Yang senior vice president, product operations; Timothy Moore vice president, South San Francisco manufacturing; Kent Lieginger vice president, managed care and customer operations; Kevin McRaith vice president, hematology sales and marketing; and John Orwin, vice president, human EGF-receptor family product sales and marketing.
Genetics Squared, of Ann Arbor, Mich., appointed Peter Lenehan chief medical officer, and David Fry chief science officer.
GlycoGenesys Inc., of Boston, appointed Peter Seeberger to its scientific advisory board and as a special consultant to the company's chemistry group.
Guava Technologies Inc., of Hayward, Calif., appointed Phillip Vorwald vice president, worldwide sales.
Hana Biosciences Inc., of South San Francisco, appointed Timothy Kinsella to its scientific advisory board.
Helix BioPharma, of Aurora, Ontario, appointed Jack Kay to its board.
Iconix Pharmaceuticals, of Mountain View, Calif., appointed Kyle Kolaja vice president of chemogenomics and toxicology, and Gene Napolitano vice president of project management and operations.